JPS6339572B2 - - Google Patents
Info
- Publication number
- JPS6339572B2 JPS6339572B2 JP52016498A JP1649877A JPS6339572B2 JP S6339572 B2 JPS6339572 B2 JP S6339572B2 JP 52016498 A JP52016498 A JP 52016498A JP 1649877 A JP1649877 A JP 1649877A JP S6339572 B2 JPS6339572 B2 JP S6339572B2
- Authority
- JP
- Japan
- Prior art keywords
- solution
- add
- substance
- water
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000243 solution Substances 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 239000000126 substance Substances 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 12
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 12
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- FPFSGDXIBUDDKZ-UHFFFAOYSA-N 3-decyl-2-hydroxycyclopent-2-en-1-one Chemical compound CCCCCCCCCCC1=C(O)C(=O)CC1 FPFSGDXIBUDDKZ-UHFFFAOYSA-N 0.000 claims description 6
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- XIWMTQIUUWJNRP-UHFFFAOYSA-N amidol Chemical compound NC1=CC=C(O)C(N)=C1 XIWMTQIUUWJNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000011609 ammonium molybdate Substances 0.000 claims description 6
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 claims description 6
- 229940010552 ammonium molybdate Drugs 0.000 claims description 6
- 235000018660 ammonium molybdate Nutrition 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 238000002331 protein detection Methods 0.000 claims description 6
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 6
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 6
- 239000003463 adsorbent Substances 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 230000001624 sedative effect Effects 0.000 claims description 2
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 claims 5
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010049040 Weight fluctuation Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- CMDGQTVYVAKDNA-UHFFFAOYSA-N propane-1,2,3-triol;hydrate Chemical compound O.OCC(O)CO CMDGQTVYVAKDNA-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1649877A JPS53101515A (en) | 1977-02-17 | 1977-02-17 | Medicine having anodyne * sedative and antiallergic activity and production thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1649877A JPS53101515A (en) | 1977-02-17 | 1977-02-17 | Medicine having anodyne * sedative and antiallergic activity and production thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS53101515A JPS53101515A (en) | 1978-09-05 |
| JPS6339572B2 true JPS6339572B2 (enrdf_load_stackoverflow) | 1988-08-05 |
Family
ID=11917938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1649877A Granted JPS53101515A (en) | 1977-02-17 | 1977-02-17 | Medicine having anodyne * sedative and antiallergic activity and production thereof |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS53101515A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1557171A1 (en) | 2002-10-31 | 2005-07-27 | VanWorld Pharmaceutical (Rugao) Company Limited | Rabbit skin comprising biological active substance and its use |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5835117A (ja) * | 1981-08-25 | 1983-03-01 | Nippon Zoki Pharmaceut Co Ltd | 新規生理活性物質ｎｓｈ |
| JPS59118711A (ja) * | 1982-12-25 | 1984-07-09 | Nippon Zoki Pharmaceut Co Ltd | 新規生理活性物質 |
| JP2651674B2 (ja) * | 1987-07-23 | 1997-09-10 | 日本臓器製薬 株式会社 | 新規生理活性物質及びその製造方法 |
| JP2539665B2 (ja) * | 1988-06-20 | 1996-10-02 | 日本臓器製薬株式会社 | 神経疾患治療剤 |
| JP2588109B2 (ja) * | 1993-03-19 | 1997-03-05 | 日本臓器製薬株式会社 | 鎮痛剤 |
| JP3213831B2 (ja) * | 1993-08-06 | 2001-10-02 | 日本臓器製薬株式会社 | 被検物質の活性測定方法 |
| JP3213832B2 (ja) * | 1993-08-06 | 2001-10-02 | 日本臓器製薬株式会社 | 被検物質の活性測定法 |
| JP2594222B2 (ja) * | 1993-09-28 | 1997-03-26 | 日本臓器製薬株式会社 | 新規生理活性物質−ｋｆ |
| JP4033936B2 (ja) * | 1997-01-08 | 2008-01-16 | 日本臓器製薬株式会社 | 一酸化窒素産生抑制剤 |
| JPH1180005A (ja) * | 1997-09-12 | 1999-03-23 | Nippon Zoki Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
| KR19990044835A (ko) | 1997-11-28 | 1999-06-25 | 고니시 진우에몬 | 생약추출물 |
| KR20010020741A (ko) | 1999-04-15 | 2001-03-15 | 고니시 진우에몬 | 신규의 생체 활성화 물질 |
| KR20010082721A (ko) | 2000-02-18 | 2001-08-30 | 고니시 진우에몬 | 지방산 함유 조성물 |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| CN100464782C (zh) | 2002-10-31 | 2009-03-04 | 日本脏器制药株式会社 | 纤维肌痛症治疗剂 |
| KR101307999B1 (ko) | 2004-12-01 | 2013-09-12 | 니폰 조키 세야쿠 가부시키가이샤 | 건조물 및 그 제조방법 |
| US20060134646A1 (en) | 2004-12-17 | 2006-06-22 | Ansari Aftab A | Method for treatment of HIV infection |
| TWI406664B (zh) | 2006-03-30 | 2013-09-01 | Univ Kyoto | 硫氧還蛋白（ｔｈｉｏｒｅｄｏｘｉｎ）產生促進劑 |
| US7923254B2 (en) * | 2006-09-06 | 2011-04-12 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for studying, determining or evaluating pharmacological actions of a test substance on an sart stressed animal |
| KR20100057535A (ko) | 2007-08-31 | 2010-05-31 | 고쿠리쓰다이가쿠호진 규슈다이가쿠 | 항암제에 의한 말초신경장애의 예방 또는 경감제 |
| TWI483729B (zh) | 2010-03-11 | 2015-05-11 | Nippon Zoki Pharmaceutical Co | 慢性前列腺炎、間質性膀胱炎及／或排尿障礙之改善或治療劑 |
| US9447466B2 (en) | 2010-06-25 | 2016-09-20 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for determination or evaluation of test substance |
| CA2808927C (en) | 2010-10-14 | 2018-10-30 | Nippon Zoki Pharmaceutical Co., Ltd. | A method for promoting the synthesis of collagen and proteoglycan in chondrocytes |
| AU2012380940B2 (en) | 2012-05-25 | 2016-08-25 | Well Resources Limited | Peptide and the use thereof |
| CN105163746A (zh) | 2013-04-30 | 2015-12-16 | 日本脏器制药株式会社 | 提取物和含有该提取物的制剂 |
| TWI705816B (zh) | 2016-01-29 | 2020-10-01 | 國立大學法人千葉大學 | 用以製造肌損傷之預防或治療劑或修復促進劑之牛痘病毒接種炎症組織萃取物之用途 |
| US11129976B2 (en) | 2016-02-24 | 2021-09-28 | Osaka University | Test method |
| JP7125733B2 (ja) * | 2016-09-14 | 2022-08-25 | 日本臓器製薬株式会社 | 肢端紅痛症の改善又は治療剤 |
| JP7064197B2 (ja) | 2016-09-23 | 2022-05-10 | 国立大学法人大阪大学 | シュワン細胞分化促進剤及び末梢神経再生促進剤 |
-
1977
- 1977-02-17 JP JP1649877A patent/JPS53101515A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1557171A1 (en) | 2002-10-31 | 2005-07-27 | VanWorld Pharmaceutical (Rugao) Company Limited | Rabbit skin comprising biological active substance and its use |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS53101515A (en) | 1978-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6339572B2 (enrdf_load_stackoverflow) | ||
| JP2539665B2 (ja) | 神経疾患治療剤 | |
| Richter | The inactivation of adrenaline in vivo in man | |
| KR100189144B1 (ko) | 신규 생리 활성 물질 | |
| JP2651674B2 (ja) | 新規生理活性物質及びその製造方法 | |
| JPS6312846B2 (enrdf_load_stackoverflow) | ||
| CN108434063A (zh) | 一种具有舒缓修复敏感肌肤功效的护肤组合物及制备与应用 | |
| JP2539669B2 (ja) | 糖尿病性神経障害治療剤 | |
| EA029649B1 (ru) | Гель на основе полифенолов гранатовой кожуры для лечения воспалительных заболеваний в гинекологии и способ его приготовления | |
| US6726932B2 (en) | Fatty acid-containing composition | |
| JPH0343279B2 (enrdf_load_stackoverflow) | ||
| JP2732379B2 (ja) | 知覚異常改善剤 | |
| JPH0228115A (ja) | 生理活性物質及び該物質を含有する医薬組成物 | |
| CN106511512A (zh) | 一种中药外用凝胶及其制备方法与应用 | |
| AU763224B2 (en) | Novel bioactivating substance | |
| CN103804207B (zh) | 芥子碱氯化盐的制备方法及其医药应用 | |
| CN110279717B (zh) | 鳄鱼甲有效组分的制备及其抗氧化、抗肝纤维化的应用 | |
| WO2024021826A1 (zh) | 一种治疗癌性疼痛的药物组合物及其制备方法 | |
| CN103933100A (zh) | 功劳木总生物碱的制备及其在预防和治疗胃溃疡药物中的应用 | |
| JPH0330598B2 (enrdf_load_stackoverflow) | ||
| JP4995727B2 (ja) | 早漏治療用薬剤の製造のためのウインターセイボリー（ｓａｔｕｒｅｊａｍｏｎｔａｎａ）またはその抽出物の使用 | |
| CN105727211A (zh) | 一种治疗人乳头瘤病毒感染的中药栓剂及其制备方法 | |
| JP2539674B2 (ja) | 新規生理活性物質 | |
| CN112294884A (zh) | 一种能快速舒缓皮肤痒感、痛感的植物组合物及其制备方法 | |
| CN1608628A (zh) | 甜叶甙r1及其衍生物作为制备防治神经退行性疾病的药物的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |